Immunology Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

This Phase 3 trial studied omalizumab, a medicine, used alone and combined with multi-allergen oral immunotherapy in children and adults with peanut and other food allergies. The goal was to help patients safely eat allergenic foods with fewer allergic symptoms. With 458 participants across the United States, the study found results that may improve how food allergies are treated and could offer more options to improve daily life for those affected.

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

This Phase 2 study tested two medicines, rituximab and tocilizumab, for patients who developed immune-related side effects due to cancer immunotherapy and depended on steroids for relief. Steroids can cause many side effects, so this study aimed to find treatments that reduce or eliminate the need for steroids. Conducted in the United States, the trial’s results are now available and may help people experiencing these difficult side effects from cancer treatments.

Donor-Derived Viral Specific T-cells (VSTs)

This Phase 1 trial explored a new treatment using donor-derived viral specific T-cells for patients who had allogeneic stem cell transplants and were at risk of viral infections. These infections are common and serious after transplant. The treatment aims to boost the body’s ability to fight viruses in a safer way and potentially reduce hospital stays and side effects from current antiviral drugs. The study is ongoing in the United States and plans to involve many participants.

Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children

This Phase 3 trial tested a nasal spray made from probiotics in children with allergic rhinoconjunctivitis, an allergy affecting the nose and eyes. The treatment aims to improve symptoms by changing the immune system and the bacteria in the respiratory tract. Conducted in Italy with 60 children, the results are still pending but could offer a new non-invasive option for managing allergies in children.

Epicutaneous Immunotherapy in Peanut Allergy in Children

This Phase 2 trial studied epicutaneous immunotherapy, which involves applying small amounts of peanut protein to the skin, in children with peanut allergy. The goal was to help children build tolerance and reduce allergic reactions to peanuts. Conducted in France with 60 participants, the results are not yet available but could lead to an additional way to protect children from severe peanut allergies.

This week saw important progress in treatments for food allergies, side effects of cancer immunotherapy, and infections after stem cell transplants. These studies bring hope for safer and more effective options to improve quality of life for patients facing immune system challenges.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.